Comparative Pharmacology
Head-to-head clinical analysis: CELONTIN versus TRIDIONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CELONTIN versus TRIDIONE.
CELONTIN vs TRIDIONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Increases levels of gamma-aminobutyric acid (GABA) in the central nervous system, possibly by inhibiting GABA transaminase or enhancing GABA release; also reduces calcium influx into neurons, stabilizing neuronal membranes.
Increases seizure threshold by modulating voltage-gated sodium channels and enhancing GABA-ergic inhibition.
300 mg orally three times daily, increased by 300 mg every 3-4 days as tolerated; usual maintenance dose 900-2400 mg/day in divided doses.
300-600 mg orally three times daily; titrate to seizure control.
None Documented
None Documented
Terminal elimination half-life: 40-60 hours in adults, 30-45 hours in children; prolonged liver disease or renal impairment may increase half-life.
16-24 hours (trimethadione); dimethadione (active metabolite) has a half-life of ~6-12 days, leading to drug accumulation.
Renal: approximately 40-60% as unchanged drug; hepatic metabolism accounts for the remainder, with metabolites excreted renally.
Renal: ~70% as unchanged drug and metabolites (including dimethadione); biliary/fecal: minimal (<10%).
Category C
Category C
Anticonvulsant
Anticonvulsant